Eucodis Bioscience, a company developing, customizing, manufacturing, and marketing enzymes for the chemical industry has entered into a research agreement with Bio Sidus, the leading biopharmaceutical company in Latin America. The agreement gives Eucodis Bioscience exclusive access - for the search of enzymes of interest - to Bio Sidus' proprietary collection of psychrophilic bacteria strains and other organisms isolated from the Antarctic and the surrounding oceans. Psychrophiles are organisms that thrive at low temperatures. Eucodis Bioscience will use its experience in enzyme development to screen the strains for enzymatic activities that can be used in industrial and other commercial applications.
"We are excited that Eucodis Bioscience gains access to Bio Sidus' collection of psychrophilic microorganisms with their wealth of hitherto untapped biological diversity," commented Rudy Pandjaitan, CEO of Eucodis Bioscience.
"The biological diversity of organisms that are adapted to an extremely cold environment offers a huge potential for the discovery and development of novel enzymes. Enzymes that enable or accelerate chemical processes at a low temperature offer tremendous commercial and environmental advantages for energy-intensive industrial processes as well as for detergents and other products for domestic applications."
Eucodis Bioscience GmbH develops, optimizes, manufactures, and markets industrial enzymes.
Bio Sidus is the leading biopharmaceutical company in Latin America. Bio Sidus currently manufactures and markets human erythropoietin, human growth hormone and human interferon Alfa 2a and 2b, amongst other proprietary biotech developments.